|
G
|
Alb
|
albumin
|
affects binding
|
ISO
|
Amsacrine analog binds to ALB protein; Amsacrine binds to ALB protein
|
CTD |
PMID:10803926 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
G
|
Ar
|
androgen receptor
|
multiple interactions
|
ISO
|
Amsacrine binds to and results in decreased activity of AR protein
|
CTD |
PMID:25752796 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
G
|
Atg7
|
autophagy related 7
|
decreases expression
|
ISO
|
Amsacrine results in decreased expression of ATG7 protein
|
CTD |
PMID:37451322 |
|
NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319
|
|
G
|
Atm
|
ATM serine/threonine kinase
|
multiple interactions
|
ISO
|
ATM protein promotes the reaction [Amsacrine results in increased phosphorylation of H2AX protein]
|
CTD |
PMID:37451322 |
|
NCBI chr 8:62,724,939...62,829,040
Ensembl chr 8:62,727,291...62,828,629
|
|
G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
increases response to substance
|
ISO
|
BAX protein results in increased susceptibility to Amsacrine
|
CTD |
PMID:16177561 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
G
|
Bcl2
|
BCL2, apoptosis regulator
|
decreases response to substance
|
ISO
|
BCL2 protein results in decreased susceptibility to Amsacrine
|
CTD |
PMID:10920913 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
G
|
Bcl2l1
|
Bcl2-like 1
|
decreases expression multiple interactions
|
ISO
|
Amsacrine results in decreased expression of BCL2L1 protein [[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; ELAVL1 protein inhibits the reaction [Amsacrine results in decreased expression of BCL2L1 mRNA]; ELAVL1 protein inhibits the reaction [Amsacrine results in increased degradation of BCL2L1 mRNA]
|
CTD |
PMID:37451322 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
G
|
Becn1
|
beclin 1
|
increases expression
|
ISO
|
Amsacrine results in increased expression of BECN1 protein
|
CTD |
PMID:37451322 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002
|
|
G
|
Casp2
|
caspase 2
|
increases splicing increases expression
|
ISO
|
Amsacrine results in increased splicing of CASP2 mRNA Amsacrine results in increased expression of CASP2 mRNA alternative form
|
CTD |
PMID:14757846 |
|
NCBI chr 4:72,116,265...72,134,023
Ensembl chr 4:72,116,246...72,134,022
|
|
G
|
Ccna2
|
cyclin A2
|
multiple interactions
|
ISO
|
Amsacrine results in increased degradation of and results in decreased expression of CCNA2 protein
|
CTD |
PMID:11774253 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
G
|
Ccnb1
|
cyclin B1
|
multiple interactions
|
ISO
|
Amsacrine results in increased degradation of and results in decreased expression of CCNB1 protein
|
CTD |
PMID:11774253 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccne1
|
cyclin E1
|
increases expression
|
ISO
|
Amsacrine results in increased expression of CCNE1 protein
|
CTD |
PMID:11774253 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
G
|
Egf
|
epidermal growth factor
|
multiple interactions
|
ISO
|
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Amsacrine
|
CTD |
PMID:16969495 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
G
|
Elavl1
|
ELAV like RNA binding protein 1
|
decreases expression multiple interactions
|
ISO
|
Amsacrine results in decreased expression of ELAVL1 protein [[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; [Amsacrine results in increased expression of MIR22] which results in decreased expression of ELAVL1 mRNA; Amsacrine results in decreased expression of and results in decreased stability of ELAVL1 mRNA; ELAVL1 protein inhibits the reaction [Amsacrine results in decreased expression of BCL2L1 mRNA]; ELAVL1 protein inhibits the reaction [Amsacrine results in increased degradation of BCL2L1 mRNA]; GLX351322 inhibits the reaction [Amsacrine results in decreased expression of ELAVL1 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631
|
|
G
|
Esr1
|
estrogen receptor 1
|
multiple interactions
|
ISO
|
Amsacrine binds to and results in decreased activity of ESR1 protein
|
CTD |
PMID:25752796 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases phosphorylation multiple interactions
|
ISO
|
Amsacrine results in increased phosphorylation of H2AX protein ATM protein promotes the reaction [Amsacrine results in increased phosphorylation of H2AX protein]
|
CTD |
PMID:37451322 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions
|
ISO
|
Amsacrine binds to and results in decreased activity of KCNH2 protein
|
CTD |
PMID:15148258 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
G
|
Map1lc3b
|
microtubule-associated protein 1 light chain 3 beta
|
increases expression
|
ISO
|
Amsacrine results in increased expression of MAP1LC3B protein
|
CTD |
PMID:37451322 |
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358 Ensembl chr16:66,574,407...66,584,358
|
|
G
|
Map2k1
|
mitogen activated protein kinase kinase 1
|
multiple interactions
|
ISO
|
MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in increased expression of MIR22 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions decreases phosphorylation
|
ISO
|
[[Amsacrine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; GLX351322 inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]; MitoTEMPO inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK1 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk12
|
mitogen-activated protein kinase 12
|
increases activity multiple interactions affects response to substance
|
ISO
|
Amsacrine results in increased activity of MAPK12 protein [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Amsacrine; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Amsacrine MAPK12 protein affects the susceptibility to Amsacrine
|
CTD |
PMID:21878638 |
|
NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
decreases phosphorylation multiple interactions
|
ISO
|
Amsacrine results in decreased phosphorylation of MAPK3 protein [[Amsacrine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of ELAVL1 mRNA] which results in increased degradation of BCL2L1 mRNA; GLX351322 inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MAP2K1 protein inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]; MitoTEMPO inhibits the reaction [Amsacrine results in decreased phosphorylation of MAPK3 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mdm2
|
MDM2 proto-oncogene
|
decreases response to substance
|
ISO
|
MDM2 promoter SNP results in decreased susceptibility to Amsacrine
|
CTD |
PMID:17575151 |
|
NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791
|
|
G
|
Mir22
|
microRNA 22
|
increases expression multiple interactions
|
ISO
|
Amsacrine results in increased expression of MIR22 [Amsacrine results in increased expression of MIR22] which results in decreased expression of ELAVL1 mRNA; MAP2K1 protein inhibits the reaction [Amsacrine results in increased expression of MIR22 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr10:60,805,331...60,805,425
Ensembl chr10:60,805,331...60,805,425
|
|
G
|
Mir25
|
microRNA 25
|
decreases expression multiple interactions
|
ISO
|
Amsacrine results in decreased expression of MIR25 SIDT2 protein promotes the reaction [Amsacrine results in decreased expression of MIR25 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr12:22,156,641...22,156,724
|
|
G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression
|
ISO
|
Amsacrine results in decreased expression of MYC mRNA
|
CTD |
PMID:11585056 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
G
|
Ncl
|
nucleolin
|
affects response to substance
|
ISO
|
NCL protein affects the susceptibility to Amsacrine
|
CTD |
PMID:16600179 |
|
NCBI chr 9:94,447,559...94,456,083
Ensembl chr 9:94,446,682...94,456,083
|
|
G
|
Nox4
|
NADPH oxidase 4
|
increases expression multiple interactions
|
ISO
|
Amsacrine results in increased expression of NOX4 protein Amsacrine results in increased expression of and results in decreased degradation of NOX4 mRNA; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 mRNA]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 protein]
|
CTD |
PMID:37451322 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Pgr
|
progesterone receptor
|
multiple interactions
|
ISO
|
Amsacrine binds to and results in decreased activity of PGR protein
|
CTD |
PMID:25752796 |
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271
|
|
G
|
Prc1
|
protein regulator of cytokinesis 1
|
decreases expression
|
ISO
|
Amsacrine results in decreased expression of PRC1 mRNA
|
CTD |
PMID:17374387 |
|
NCBI chr 1:143,659,312...143,681,019
Ensembl chr 1:143,659,481...143,681,012
|
|
G
|
Rad51
|
RAD51 recombinase
|
affects response to substance
|
ISO
|
RAD51 protein affects the susceptibility to Amsacrine
|
CTD |
PMID:16600179 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Rarb
|
retinoic acid receptor, beta
|
increases expression
|
ISO
|
Amsacrine results in increased expression of RARB mRNA alternative form
|
CTD |
PMID:17608728 |
|
NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040
|
|
G
|
Sidt2
|
SID1 transmembrane family, member 2
|
multiple interactions increases expression
|
ISO
|
SIDT2 protein promotes the reaction [Amsacrine results in decreased expression of MIR25 protein]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 mRNA]; SIDT2 protein promotes the reaction [Amsacrine results in increased expression of NOX4 protein] Amsacrine results in increased expression of SIDT2 protein
|
CTD |
PMID:37451322 |
|
NCBI chr 8:55,129,091...55,146,446
Ensembl chr 8:55,129,091...55,145,408
|
|
G
|
Thra
|
thyroid hormone receptor alpha
|
multiple interactions
|
ISO
|
Amsacrine binds to and results in decreased activity of THRA protein
|
CTD |
PMID:25752796 |
|
NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657
|
|
G
|
Tnfrsf11b
|
TNF receptor superfamily member 11B
|
increases expression
|
ISO
|
Amsacrine results in increased expression of TNFRSF11B mRNA
|
CTD |
PMID:11459812 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075
|
|
G
|
Tnfsf11
|
TNF superfamily member 11
|
decreases expression
|
ISO
|
Amsacrine results in decreased expression of TNFSF11 mRNA
|
CTD |
PMID:11459812 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
G
|
Top2a
|
DNA topoisomerase II alpha
|
multiple interactions decreases response to substance affects response to substance
|
ISO
|
[EGF protein results in decreased expression of TOP2A protein] which results in decreased susceptibility to Amsacrine; [MAPK12 protein results in increased phosphorylation of TOP2A protein] which results in increased susceptibility to Amsacrine; [MAPK12 protein results in increased stability of TOP2A protein] which results in increased susceptibility to Amsacrine TOP2A gene mutant form results in decreased susceptibility to Amsacrine; TOP2A protein mutant form results in decreased susceptibility to Amsacrine TOP2A protein modified form affects the susceptibility to Amsacrine
|
CTD |
PMID:1651812 PMID:10727526 PMID:11470519 PMID:11676865 PMID:12569090 PMID:16969495 PMID:21878638 More...
|
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
G
|
Top2b
|
DNA topoisomerase II beta
|
decreases response to substance
|
ISO
|
TOP2B protein mutant form results in decreased susceptibility to Amsacrine
|
CTD |
PMID:15322234 PMID:16239602 PMID:16549872 |
|
NCBI chr15:11,482,089...11,542,464
Ensembl chr15:11,482,089...11,542,464
|
|
G
|
Tp53
|
tumor protein p53
|
increases activity increases expression multiple interactions increases glutathionylation
|
ISO
|
Amsacrine analog results in increased activity of TP53 protein Amsacrine results in increased expression of TP53 protein Amsacrine results in increased stability of and results in increased activity of TP53 protein Amsacrine results in increased glutathionylation of TP53 protein
|
CTD |
PMID:11774253 PMID:12082016 PMID:16177561 PMID:17555331 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Tp53i3
|
tumor protein p53 inducible protein 3
|
increases expression
|
ISO
|
Amsacrine results in increased expression of TP53I3 mRNA
|
CTD |
PMID:17374387 |
|
NCBI chr 6:33,537,779...33,545,204
|
|
G
|
Ube2c
|
ubiquitin-conjugating enzyme E2C
|
decreases expression
|
ISO
|
Amsacrine results in decreased expression of UBE2C mRNA
|
CTD |
PMID:17374387 |
|
NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678
|
|
G
|
Wrn
|
WRN RecQ like helicase
|
increases response to substance
|
ISO
|
WRN gene mutant form results in increased susceptibility to Amsacrine
|
CTD |
PMID:10725663 |
|
NCBI chr16:65,466,552...65,602,951
Ensembl chr16:65,456,254...65,602,951
|
|